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 Introduction 
 Complex regional pain syndrome (CRPS) and fibro-
myalgia (FM) are chronic pain syndromes which are 
 often preceded by extremely stressful experiences and 
other major adverse life events  [1–7] . CRPS as well as FM 
have been classified as so-called central sensitization 
 syndromes  [8, 9] involving hyperexcitement of the cen-
tral neurons through various synaptic activities and 
 neurotransmitters leading to dysfunction of brain areas 
which regulate pain perception and stress responses. 
 Both disorders, however, differ in type and localiza-
tion of pain. CRPS is a localized neuropathic pain syn-
drome usually occurring after a limb trauma without 
(type I) or with (type II) an injury of a peripheral nerve. 
Pain in CRPS patients is not proportionally related to the 
initial injury and does not follow a nerve innervation pat-
tern. It is associated with autonomic dysregulation, swell-
ing, motor and trophic signs  [8] . FM is defined according 
to the classification criteria of the American College of 
Rheumatology which require the presence of self-report-
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 Abstract 
 Background: The complex regional pain syndrome (CRPS) 
and fibromyalgia (FM) are chronic pain syndromes occurring 
in highly stressed individuals. Despite the known connec-
tion between the nervous system and immune cells, infor-
mation on distribution of lymphocyte subsets under stress 
and pain conditions is limited.  Methods: We performed a 
comparative study in 15 patients with CRPS type I, 22 pa-
tients with FM and 37 age- and sex-matched healthy controls 
and investigated the influence of pain and stress on lympho-
cyte number, subpopulations and the Th1/Th2 cytokine ra-
tio in T lymphocytes.  Results: Lymphocyte numbers did not 
differ between groups. Quantitative analyses of lymphocyte 
subpopulations showed a significant reduction of cytotoxic 
CD8+ lymphocytes in both CRPS (p  ! 0.01) and FM (p  ! 0.05) 
patients as compared with healthy controls. Additionally, 
CRPS patients were characterized by a lower percentage of 
IL-2-producing T cell subpopulations reflecting a diminished 
Th1 response in contrast to no changes in the Th2 cytokine 
profile.  Conclusions: Future studies are warranted to answer 
whether such immunological changes play a pathogenetic 
role in CRPS and FM or merely reflect the consequences of a 
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ed chronic widespread pain and 11 or more anatomically 
defined tender points upon palpation  [10] . FM patients 
exhibit an exaggerated pain response upon digital pres-
sure and are hypersensitive to heat, cold, electric stimuli 
as well as ischemia in many areas of the human body. Ini-
tial physical trauma may be involved in the pathogenesis 
of FM  [9] ; however, traumatic events are observed much 
less frequently than in CRPS.
 Despite the known connection between the nervous 
system and immune cells  [11–16] , information on distri-
bution of lymphocyte subsets under stress and pain con-
ditions is limited  [17] . In rodents, acute stress reduces 
CD4+ cells  [18] , and chronic social stress induces a de-
crease in CD4+ and CD8+ lymphocytes  [19] . Acute hu-
man stress is known to increase CD8+ lymphocytes  [20–
22] as well as to decrease CD4+ cells and the ratio of 
CD4+/CD8+ cells  [23] . In contrast, in prolonged human 
stress responses such as posttraumatic stress disorder, 
lymphocyte subsets are not deranged  [24] . With respect 
to chronic pain, information on alterations of lympho-
cyte subsets is inconsistent; cluster headache and low 
back pain lower the CD4+ subpopulation  [25] , while mi-
graine is characterized by decreased levels of CD8+ T 
lymphocytes  [26] .
 T cells may be functionally defined by their cytokine 
profile. With regard to the CD4+ T helper (Th) cells, an 
adequate host immune response against infection is 
largely dependent on the activation of their two function-
ally distinct subsets, Th1 and Th2 cells  [12, 13] . The Th1/
Th2 balance is a prerequisite for the full functionality of 
immunity. Th1 cells secrete more interferon-  and inter-
leukin (IL)-2 and stimulate (cellular) type 1 immunity. 
Th1 responses promote production of opsonizing anti-
bodies (e.g., IgG1) and induce cellular cytotoxicity by ac-
tivation of macrophages with powerful phagocytic activ-
ity. Th2 lymphocytes produce more IL-4 and IL-10 and 
induce humoral type 2 immunity with promotion of IgE 
and IgG4 production, thereby fine-tuning B cell antibody 
production. Autoimmunity induces an imbalance be-
tween the Th1 and Th2 response with a Th1 dominance. 
Trauma and cancer-bearing states are characterized by 
an increase in the Th2 cytokine production. To our 
knowledge, there are no studies in the literature examin-
ing Th1/Th2 balance in CRPS or FM, respectively.
 Therefore, this study intended to test the hypothesis 
that lymphocyte subsets and, especially, percentages of T 
cell subsets producing proinflammatory and anti-in-
flammatory cytokines are different in CRPS and FM pa-
tients and related to the levels of self-perceived emotional 
stress.
 Materials and Methods 
 The study was approved by the local ethics committee (proto-
col No. 324/02) and conducted in accordance with the guidelines 
of the declaration of Helsinki and its amendment in Tokyo, 1975, 
and Hong Kong, 1989. Data protection met the standards set by 
the German law.
 Patients, Definitions and Entry Criteria 
 Fifteen CRPS type I patients classified according to the criteria 
of the International Association for the Study of Pain (IASP)  [27] 
and Bruehl et al.  [28] and 22 patients with FM defined according 
to the American College of Rheumatology  [10] admitted to the 
Interdisciplinary Pain Clinic of the University Clinic of Munich, 
Germany were included in this study ( table 1 ). FM patients had 
undergone a thorough evaluation by experienced rheumatolo-
gists in the setting of a university-affiliated center during which 
the diagnosis of FM was confirmed; other inflammatory or non-
inflammatory conditions mimicking FM were systematically 
 excluded. Exclusion criteria were pregnancy, infection or other 
inflammation disorders, cancer, concurrent muscle or joint dis-
eases, motor trauma or immunosuppressive medication (e.g., 
 glucocorticoids). Patients with comorbid major depressive disor-
ders or anxiety disorders were excluded. CRPS and FM patients 
abstained from intake of their current medication (tramadol, 
 amitriptyline, diclofenac, ibuprofen, metamizole,   -aminobutyr-
ic acid, or acetaminophen) for a period of 24 h. Age- and sex-
matched healthy subjects (n = 37) served as controls.
 Quantification of Pain and Stress Severity in CRPS and
FM Patients 
 The mean pain score at the time of the assessment was deter-
mined by using a visual analogue scale with a range of 0–10 (VAS). 
The intensity of emotional stress symptoms were measured using 
the German Version of the Post-traumatic Stress Symptom 10-
Questionnaire (PTSS-10). This instrument records the presence 
and intensity of 10 common stress symptoms: (1) sleep distur-
Table 1. Baseline data of healthy volunteers and chronic pain pa-
tients (mean 8 SEM)
Healthy
volunteers
(n = 37)
CRPS
patients
(n = 15)
FM
patients
(n = 22)
Age, years 52.282.1 53.984.1 53.182.1
Gender (female/male) 32/5 15/0 17/5
Inflammation parameters
Leukocytes, 103 cells/l 7.480.6 7.180.5 7.680.5
Leukocyte subpopulations, %
Neutrophils 59.281.2 60.982.5 60.681.9
Lymphocytes 23.481.0 20.781.8 20.781.3
Monocytes 6.680.3 5.980.3 6.180.4
Eosinophils 2.080.2 3.080.5 3.180.4
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bance, (2) nightmares, (3) depression, (4) hyperalertness, (5) with-
drawal (emotional numbing and inability to care for others), (6) 
generalized irritability, (7) frequent changes in mood, (8) guilt, (9) 
fear and avoidance reactions when reminded of hospitals and dis-
eases and (10) increased muscle tension. Patients rate their symp-
toms, using a scale from 1 (never) to 7 (always)  [29, 30] . 
 Biochemical Measurements 
 Reagents. Fluorescence-activated cell sorting (FACS) permea-
bilizing solution, SimulTest IMK plus  kit, bovine serum albu-
min (BSA) and monoclonal antibodies [peridinin-chlorophyll-
protein complex (PerCP)-conjugated anti-CD3, anti-CD4 and 
anti-CD8; fluorescein isothiocyanate (FITC)-conjugated anti-
human IL-2 and anti-human interferon-  ; R-phycoerythrin (PE)-
conjugated anti-human-IL-4 and anti-human-IL-10] were ob-
tained from Becton Dickinson (Heidelberg, Germany). Hanks’ 
buffered salt solution (HBSS), phosphate-buffered saline (PBS) 
and 1% paraformaldehyde were manufactured from soluble in-
gredients by the hospital’s own pharmacy. RPMI 1640, ionomycin 
and brefeldin A were purchased from Sigma-Aldrich (Taufkir-
chen, Germany).
 Lymphocyte Populations. For immunophenotyping of lym-
phocyte populations a SimulTest IMK plus was used. Venous hep-
arinized blood samples (heparin activity 10 IU/ml) were incu-
bated with each of six antibody reagents from the SimulTest IMK 
plus kit for 20 min at room temperature. Subsequently, the stained 
samples were treated with lysing solution to eliminate erythro-
cytes for 10 min, washed with cold HBSS solution and put on ice 
until f low-cytometric analysis.
 Intracellular Cytokine Synthesis. Heparinized blood (heparin 
activity 10 IU/ml) was diluted with RPMI 1640 (ratio 1: 1), and 
incubated for 4 h at 37 ° C, 7% CO 2 , with 7.5 nmol/l phorbol my-
ristate acetate and 1.34 nmol/ml ionomycin. After 1 h of incuba-
tion, 1.4   mol/l brefeldin A was added. Subsequently, cells were 
incubated for 20 min at room temperature with PerCP-labeled 
monoclonal antibodies with specificity for surface antigens (CD3, 
CD4, CD8). Afterwards, erythrocytes were lysed with FACS lys-
ing solution for 60 min. After washing of cells with a buffer (PBS, 
BSA 0.5%, NaN 3 0.1%), they were permeabilized by incubation 
with permeabilizing solution for 10 min and stained with mono-
clonal antibodies against cytokines (FITC-marked: anti-interfer-
on-  , anti-IL-2; PE-marked: anti-IL-4, anti-IL-10). After a 2-fold 
washing, cells were fixed with paraformaldehyde 1% and put on 
ice until analysis by flow cytometry as described below. However, 
for each sample in the assay an unstimulated and activated intra-
cellular isotype staining control was run. 
 Control of Changes in Intracellular Cytokine Production for 
Changes in a Lymphocyte Subpopulation of Interest. Since an im-
munomodulating factor, like a stress hormone, might not only 
affect the capacity of a given lymphocyte subset to produce a reg-
ulatory cytokine, but also the blood concentration of the respec-
tive lymphocyte subset, we determined the ratio between the ob-
served change in the cytokine-producing cells and the change of 
the lymphocyte subset. Specifically, we looked at whether a de-
crease in the IL-2-producing CD8+ cells was as strong as the re-
duction in the number of CD8+ lymphocytes.
 Flow Cytometry. Samples were quantitatively analyzed by the 
use of a Becton Dickinson FACScan (Becton Dickinson, San Jose, 
Calif., USA) equipped with an argon laser emitting light at 488 
nm. During the study period, the instrument was intermittently 
calibrated and standardized by Calibrite beads (Becton Dickin-
son, Erembodegen-Aalst, Belgium).
 Lymphocyte subpopulations were obtained following gating 
of lymphocytes on SSC/FSC dot plots and referred to the Simul-
SET Software User’s Guide. 
 For intracellular cytokine analyses, a total of 10,000 events 
was collected. Lymphocytes were identified by means of their 
light SSC/FSC characteristics. The dual staining of samples al-
lowed for discrimination of different CD-positive lymphocyte T 
cell subpopulations (CD3, CD4, CD8) by live gating on the SSC/
FL3 dot plots followed by analyses of the percentage of cells pro-
ducing IL-2 and interferon-  and on the SSC/FL1 dot plots or IL-
4 and IL-10 on the SSC/FL2 dot plots ( fig. 1 ). The specific response 
of cells was obtained by subtraction of the percentage of the iso-
type-corrected response of the unstimulated sample from the 
percentage of the isotype-corrected activated sample. 
 Statistics 
 Data analyses were performed with commercially available 
software (SPSS 13.0; SPSS, Chicago, Ill., USA). Normal distri-
bution of data was tested by the Kolmogorov-Smirnov test. Com-
parisons between independent groups were performed by one-
way ANOVA followed by a post hoc correction for multiple 
 comparisons using the Bonferroni method. Correlations were an-
alyzed using Pearson’s correlation coefficient for normally dis-
tributed data. Data are considered to be significantly different at 
p  ! 0.05. Results are expressed as mean  8 SEM.
 Results 
 Baseline Characteristics 
 There were no significant differences between healthy 
volunteers, CRPS and FM patients for baseline character-
istics, leukocyte numbers and their subpopulations ( ta-
ble 1 ). 
 Quantification of Disease Severity in Chronic Pain 
Patients 
 Both CRPS and FM patients had evidence of severe 
chronic pain and stress as shown by scores on the VAS 
and the PTSS-10 instrument ( table 2 ). PTSS-10 stress 
symptom scores in both CRPS and FM patients were 
Table 2. Severity of pain and stress (mean 8 SEM) in healthy 
subjects and chronic pain patients
Healthy volun-
teers (n = 37)
CRPS patients
(n = 15)
FM patients
(n = 22)
VAS – 4.080.9 6.481.4
PTSS-10 21.387.0 29.483.1* 46.783.5**
* p < 0.05; ** p < 0.0001.
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massively increased and significantly higher than values 
for healthy individuals (CRPS: p  ! 0.05; FM: p  ! 
0.0001). 
 Lymphocyte Subpopulations 
 The number of cytotoxic T cells (CD8+) was signif-
icantly  diminished   in   patients   with   CRPS   (p    !   0.01)  
and FM (p  ! 0.05) as compared with healthy volunteers 
( fig. 2 ). However, the CD4/CD8 ratio increased only in 
CRPS patients to a significant extent (healthy volunteers: 
2.2  8 0.1; CRPS patients: 2.8  8 0.2; p  ! 0.01). 
 The proportion of CD8+ subset correlated negatively 
with the PTSS-10 score in FM patients (r = –0.55; p  ! 0.05; 
 fig. 3 ), but not in CRPS patients. No correlation was found 
for CD8+ subsets and VAS scores in both CRPS and 
FM.
 With regard to the numbers of B cells (CD19+), T cells 
(CD3+), helper T cells (CD4+), natural killer cell popula-
tion (CD3–CD16+CD56+) and CD3+CD16+CD56+ lym-
phocytes, no differences were observed between chronic 
pain patients and healthy volunteers, respectively (data 
not shown).
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 Fig. 2. Plots of the absolute numbers of CD8+ lymphocytes per 
microliter in healthy volunteers (n = 37), patients with CRPS (n = 
15) and FM (n = 22). The top of the box represents the 75th per-
centile and the bottom the 25th percentile. The horizontal line in 
the box represents the median value, and the lines above and be-
low the box are whiskers to the 95th and 5th percentiles, respec-
tively. 
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 Intracellular Cytokine Production 
 With regard to the percentages of IL-2-producing 
CD3+, CD4+ and CD8+ lymphocytes ( fig. 4 ), lower val-
ues were obtained in CRPS patients (CD3+, p  ! 0.05; 
CD4+, p  ! 0.05; CD8+, p  ! 0.01), but not in FM patients 
(CD3+, p = 0.13; CD4+, p = 0.36; CD8+, p = 0.12). When 
the decrease in IL-2-producing CD8+ cells was controlled 
for the decrease in the CD8+ cells, the decline of IL-2 
positive cells was 1.6-fold stronger than that of CD8+ 
cells. 
 When compared to healthy volunteers, no significant 
differences were observed for percentages of CD3+, 
CD4+ and CD8+ lymphocytes of CRPS and FM patients 
producing proinflammatory interferon-  . However, 
CRPS patients showed enhanced anti-inflammatory IL-
4 and immunoregulatory IL-10 production (IL-4: CD3+, 
p = 0.45; CD4+, p = 0.37; CD8+, p = 0.45; IL-10: CD3+,
p = 0.05; CD4+, p = 0.17; CD8+, p = 0.47) without reach-
ing significance ( table 3 ). Similarly, FM patients were 
also characterized by a tendency of increased IL-4 
(CD3+, p = 0.05; CD4+, p = 0.05; CD8+, p = 0.12) and 
IL-10 production (CD3+, p = 0.06; CD4+, p = 0.45; CD8+, 
p = 0.97).
 The Th1/Th2 ratios calculated on the basis of the per-
centages or the absolute number of Th cells producing 
cytokines were significantly different between healthy 
volunteers and CRPS patients (both p  ! 0.05).
 Discussion 
 This study compared lymphocyte numbers, subpopu-
lations and their intracellular cytokine production in pa-
tients with CRPS, FM and healthy controls. CRPS and 
FM patients were selected because these patients suffer 
from chronic pain syndromes accompanied by a high de-
gree of emotional stress. Major findings of this study are: 
(1) total lymphocyte numbers did not differ between 
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healthy volunteers and both groups of stressed chronic 
pain patients, (2) quantitative analyses of lymphocyte 
subpopulations showed a clear reduction of the cytotoxic 
CD8+ lymphocytes in both CRPS and FM patients as 
compared with healthy controls, and (3) CRPS patients 
were characterized by a lowered percentage of IL-2-pro-
ducing CD3+/CD4+/CD8+ T cells reflecting a dimin-
ished Th1 response in contrast to no changes in the Th2 
cytokine profile, an effect which was not seen in FM pa-
tients. 
 Decrease in the CD8+ Lymphocyte Subpopulation in 
Chronic Pain 
 Only a few trials on immunity in chronic stress and 
pain have been published to date and even fewer ad-
dressed CRPS and FM. It is known that lymphocytes 
show an altered subset distribution under conditions of 
stress and pain  [21–23, 25, 26] . We noticed significantly 
decreased numbers of cytotoxic CD8+ lymphocytes in 
both chronic pain patient groups as it has been described 
for chronic tension-type headache  [31] and migraine suf-
ferers  [26, 31] . However, our study did not confirm either 
changes in lymphocyte counts or percentages of CD3+ 
and CD4+ cells  [23, 25] in stressed pain patients. 
 Cytotoxic CD8+ T cells play an important role in the 
recognition and destruction of cells expressing foreign 
antigens, e.g. of viral or tumor origin  [32, 33] . It is known 
that pediatric patients with a persistent lack in CD8+ T 
cells develop numerous infections attributable to bacteria 
and fungi  [34] . However, further studies are needed to 
determine whether a diminished number of CD8+ T cells 
leads to increased susceptibility of chronic pain patients 
towards infections and tumor development.
 The decrease in CD8+ lymphocytes is known to result 
in part from chronic stress  [19, 35] mediated through the 
activation of the sympathetic nervous system. This is cor-
roborated by our finding of a negative correlation be-
tween PTSD scores and CD8+ T cell proportion in FM 
patients. The absence of a correlation in CRPS patients is 
probably due to the smaller sample size. Furthermore, it 
should be taken into consideration that PTSS-10 scores in 
CRPS patients show a small range of variation making 
detection of statistically significant correlations difficult. 
Interestingly, pain magnitude did not influence CD8+ 
subsets suggesting that pain alone is not the all-dominant 
factor in CD8+ cell decrease.
 Decreased Intracellular IL-2 Production by
T Lymphocytes in Contrast to an Unchanged
Th2 Cytokine Profile in CRPS 
 Besides cytotoxic CD8+ T cells, the other and most 
important fraction of CD3+ T lymphocytes is represent-
ed by CD4+ Th cells. Naive CD4+ Th cells (Th0) can dif-
ferentiate into functionally distinct subsets, Th1 and Th2 
cells. Th1 cells secrete more interferon-  and IL-2 and 
stimulate type 1 immunity participating in cellular im-
mune responses against intracellular pathogens like vi-
ruses and some bacteria. Th2 cells produce more IL-4 
and IL-10 and induce humoral type 2 immunity  [12, 13] . 
In our study, CRPS patients were characterized by a sig-
nificant decrease in IL-2-producing percentages of CD3+ 
T lymphocytes, CD4+ Th cells and CD8+ cytotoxic T 
cells ( fig. 4 ). Based on these findings one might conclude 
a reduced Th1 response.
 The impaired capacity of CD8+ cells to produce IL-2, 
however, cannot fully be explained by a decrease in the 
absolute number of circulating CD8+ cells because the 
decrease in IL-2-positive cells was much more pro-
nounced than the reduction in the CD8+ lymphocyte 
blood count. As the decrease in IL-2 production in CD8+ 
cells was over-proportional to the decline in CD8+ cell 
counts, one might suggest these changes to be indepen-
dent phenomena. In this regard it is interesting to note 
that also CD4+ T lymphocyte exhibited significantly less 
IL-2 production in CRPS patients, irrespective of the 
number of CD4+ cells in blood. This might be in further 
support of a factor or factors able to selectively decrease 
IL-2 production without suppressing the number of cir-
culating CD4+ lymphocytes. 
 In contrast, no significant changes were observed for 
IL-2-producing T cells of FM patients. Both patient 
Table 3. Intracellular cytokine production by T lymphocyte sub-
populations (mean 8 SEM)
Healthy volun-
teers (n = 37)
CRPS patients
(n = 15)
FM patients
(n = 22)
Interferon--producing lymphocytes, %
CD3+ 32.183.3 34.883.5 37.782.7
CD4+ 27.485.5 33.384.7 35.083.8
CD8+ 52.084.8 52.883.7 62.683.9
IL-4-producing lymphocytes, %
CD3+ 3.280.5 3.880.5 5.280.5
CD4+ 2.880.9 3.880.8 4.880.7
CD8+ 6.581.3 5.381.1 6.881.0
IL-10-producing lymphocytes, %
CD3+ 1.480.2 2.380.3 1.980.2
CD4+ 1.080.2 2.480.7 1.680.9
CD8+ 2.580.4 2.980.3 2.581.5
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groups showed a slight, nonsignificant increase in their 
anti-inflammatory IL-4 and IL-10 production suggesting 
a minimally enhanced Th2 response. The Th1/Th2 ratio 
was significantly decreased in CRPS patients only.
 Although polarization of the immune response has 
been documented in many other clinical conditions  [36–
41] , the exact cause for a Th1/Th2 imbalance – as ob-
served in our CRPS patients – still remains unknown. 
 Stress may influence the differentiation of bipotential 
Th cells away from a Th1 phenotype toward a Th2 phe-
notype. Early studies in animals revealed that sympa-
thetic stimulation is able to inhibit Th1 responses via   -
adrenergic receptor stimulation  [42, 43] . It is known that 
sympathetic activation of the human nervous system is 
associated with the release of catecholamines and an en-
hanced Th2 cytokine production  [44] . Both CRPS  [45] 
and FM  [46] patients were shown to exhibit increased 
noradrenaline levels. However, it is difficult to explain 
why the Th1/Th2 imbalance only occurs in CRPS pa-
tients and not in FM subjects. It could be that, conversely, 
predominance of a Th2-mediated immune response may 
induce antigen-specific B lymphocytes to produce spe-
cific antibodies which promote a secondary enhance-
ment of the Th1 response leading to an autoimmune clin-
ical picture, respectively  [47] . This hypothesis is support-
ed by an increased frequency of thyroid antibodies in FM 
 [48] . The form of Th1/Th2 imbalance due to catechol-
amine release could be blocked by   -adrenoceptor an-
tagonists  [49] which might be a therapeutic alternative in 
some of the CRPS patients. 
 Second, a reduced Th1 response could be elicited by a 
strong Th2 response induced by low affinity interactions 
of T cell receptors with relatively low doses of antigen or 
peptide ligands  [50] . In CRPS patients, this syndrome 
might develop after limb injury as a result of increased 
(neuron-)peptide levels  [51] and additional infections  [52] . 
In FM, trauma or infections occur much less frequently 
than in CRPS  [53] ; thus, associated peptide or antigen li-
gands as a cause for Th2 polarization are rarely possible.
 As a third mechanism, glucocorticoids might act di-
rectly or indirectly via a decrease in IL-12 or IFN-  pro-
duction, thereby attenuating a Th1 response. In this way, 
an elevation of plasma cortisol could induce a decrease in 
the Th1 products resulting in an imbalance between Th1/
Th2 cytokines  [54] . However, no changes of plasma cor-
tisol could be detected in CRPS  [52] . Furthermore, in 
contrast, glucocorticoids are considered as a therapeutic 
option in early CRPS  [55] .
 In addition, altered dehydroepiandrosterone (DHEA) 
levels which occur under acute and chronic inflamma-
tory conditions  [56, 57] may also exert some influence on 
Th1 and Th2 cytokines. In vitro DHEA was able to de-
crease Th1 and increase Th2 cytokine production  [58] . 
The role of DHEA in chronic pain patients is still not 
characterized and represents an emerging field of inves-
tigations. 
 Study Limitations 
 Our study has several limitations. A possible con-
founding factor in our study is the concurrent use of an-
algetic and antidepressive medication. A prolonged wash-
out period of all analgetic and antidepressive medication 
in chronic pain patients is difficult to be completely 
achieved and may be ethically unacceptable. However, 
patients abstained from intake of drugs for a period of 
24 h. A direct interaction between the use of opioids and 
immunological mechanisms cannot be definitely exclud-
ed  [59] . Despite an in vitro induction of apoptosis by tri-
cyclic antidepressants  [60] , clinically used amitryptiline 
is not known to influence leukocyte functions. The half-
life of the other drugs ranging between 1.5 and 6 h is in 
our opinion too short to affect lymphocyte function be-
cause the time interval between the intake of the last dos-
age and blood withdrawal was longer than 24 h.
 Finally, a comparison between intracellular and se-
creted cytokines, a more detailed analysis of lymphocyte 
subpopulations such as regulatory T cells, functional as-
says of such lymphocyte subpopulations and determina-
tion of hormone secretion are lacking in our study.
 Conclusion 
 CRPS and FM patients show decreased numbers of 
CD8+ cells probably due to a stress-associated activation 
of the sympathetic nervous system. CRPS patients are 
characterized by a diminished Th1 response, as suggest-
ed by an attenuated intracellular IL-2 production. Future 
studies are warranted to answer whether such immuno-
logical changes play a pathogenetic role in CRPS and FM 
or merely reflect the consequences of a pain-induced 
neurohumoral stress response.
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